BioMarin withdraws submission for Kyndrisa

27 June 2016 - On 31 May 2016, BioMarin officially notified the CHMP that it wishes to withdraw its application for a marketing authorisation for Kyndrisa (drisapersen) for the treatment of Duchenne muscular dystrophy.

Kyndrisa was expected to be used for the treatment of Duchenne muscular dystrophy in patients aged 5 years and older who are able to walk and whose disease is due to certain genetic mutations (defects) that can be treated with ‘exon 51 skipping technology’.

View EMA statement

Michael Wonder

Posted by:

Michael Wonder